Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Achillion Pharmaceut (ACHN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 398,415
  • Shares Outstanding, K 137,860
  • Annual Sales, $ 15,000 K
  • Annual Income, $ -61,710 K
  • 36-Month Beta 1.52
  • Price/Sales 26.56
  • Price/Cash Flow N/A
  • Price/Book 1.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.69 +7.43%
on 12/15/17
3.70 -21.89%
on 11/16/17
-0.14 (-4.62%)
since 11/15/17
3-Month
2.69 +7.43%
on 12/15/17
4.82 -40.04%
on 10/06/17
-0.81 (-21.89%)
since 09/15/17
52-Week
2.69 +7.43%
on 12/15/17
5.66 -48.94%
on 08/09/17
-1.22 (-29.68%)
since 12/15/16

Most Recent Stories

More News
Allergan Inks Deal to Buy Texas-Based Repros Therapeutics

Allergan (AGN) signs a definitive contract to acquire Texas-based Repros Therapeutics, which is focused on developing new drugs to treat hormonal and reproductive system disorders.

CORT : 16.52 (-4.34%)
RPRX : 0.66 (unch)
ACHN : 2.89 (unch)
AGN : 171.48 (+0.32%)
Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma

Merck (MRK) informs that the FDA grants a priority review to its supplemental biologics license application looking for its marketed drug Keytruda's label expansion for a rare lymphoma indication.

CORT : 16.52 (-4.34%)
ACHN : 2.89 (unch)
MRK : 55.97 (-0.07%)
LLY : 87.25 (+0.87%)
Revance's Neuromodulator Injection Positive in Phase III

Revance (RVNC) releases positive top-line data from two pivotal phase III trials, evaluating RT002 for reducing wrinkles between the brows. The studies meet both primary and secondary endpoints.

CORT : 16.52 (-4.34%)
ACHN : 2.89 (unch)
AGN : 171.48 (+0.32%)
RVNC : 32.45 (+0.93%)
AstraZeneca's COPD Drug Succeeds in Label Expansion Study

AstraZeneca (AZN) releases positive top-line data from a phase IV study, evaluating label expansion of Tudorza for chronic obstructive pulmonary disease with cardiovascular risk factors.

CORT : 16.52 (-4.34%)
AZN : 33.02 (-0.81%)
ACHN : 2.89 (unch)
AGN : 171.48 (+0.32%)
Today's Research Reports on Trending Tickers: Achillion Pharmaceuticals and Zynerba Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / December 5, 2017 / U.S. markets saw mixed Monday as the Dow reached a new record after investors celebrated the passing of a bill to overhaul the country's tax system while...

XLF : 27.92 (+0.83%)
ACHN : 2.89 (unch)
ZYNE : 11.87 (+3.94%)
Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug

Pfizer (PFE) inks a deal to buy exclusive rights to develop and commercialize Basilea Pharmaceutica's anti-fungal treatment, Cresemba, in the Asia-Pacific region and China.

CORT : 16.52 (-4.34%)
AZN : 33.02 (-0.81%)
ACHN : 2.89 (unch)
PFE : 37.08 (+1.70%)
Celldex Begins Phase I Trial on Cancer Candidate CDX-1140

Celldex (CLDX) commences a phase I study on CDX-1140 for patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of the candidate at different dose levels.

CORT : 16.52 (-4.34%)
CLDX : 2.94 (+0.68%)
ACHN : 2.89 (unch)
BMY : 62.37 (+0.39%)
Merck Announces $10 Billion Buyback, Hikes Dividend by 2.1%

Merck (MRK) rewards shareholders with a hike in quarterly dividend. Also, the company's board of directors sanctions a new stock buyback plan.

LGND : 133.74 (-1.69%)
ACHN : 2.89 (unch)
JNJ : 141.85 (+0.14%)
MRK : 55.97 (-0.07%)
AstraZeneca Files for Label Expansion of Tagrisso in Japan

AstraZeneca (AZN) files a regulatory application in Japan to expand the label of Tagrisso for first-line treatment of patients with non-small cell lung cancer.

LGND : 133.74 (-1.69%)
AZN : 33.02 (-0.81%)
ACHN : 2.89 (unch)
RHHBY : 30.7500 (+0.39%)
Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler

Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.

LGND : 133.74 (-1.69%)
INVA : 13.48 (+1.51%)
ACHN : 2.89 (unch)
GSK : 34.87 (-1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused...

See More

Key Turning Points

2nd Resistance Point 3.06
1st Resistance Point 2.97
Last Price 2.89
1st Support Level 2.83
2nd Support Level 2.78

See More

52-Week High 5.66
Fibonacci 61.8% 4.53
Fibonacci 50% 4.18
Fibonacci 38.2% 3.82
Last Price 2.89
52-Week Low 2.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.